Entering text into the input field will update the search result below

Feuerstein article hits Northwest Biotherapeutics

  • Shares of Northwest Biotherapeutics (OTCQB:NWBO) are suffering, off 7% in premarket action.
  • Not helping the cause is TheStreet's Adam Feuerstein, who says DCVax "will fail just like ICT-107 failed because dendritic cancer vaccines are too weak to overcome cancer's innate ability to overpower or evade the body's immune system."
  • The thrust of the argument here is that positive data from early studies of the DCVax were misleading because the 20 brain cancer patients "were handpicked for treatment."
  • Feuerstein says the same was true of a small Phase 1 study of ImmunoCellular's ICT-107, which ended up missing its primary OS endpoint in a larger study (triggering a spectacular sell-off last Wednesday).
  • Feuerstein is responding to an article by SA contributor Josh Ginsburg who, on Monday, explained why he thinks NWBO "is different."

Recommended For You

About NWBO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NWBO--
Northwest Biotherapeutics, Inc.